• NEWS . 07 Sep 2020
  • Ticagrelor showed greater antiplatelet efficacy than clopidogrel in diabetic patients post-PCI

  • Clopidogrel is currently the only P2Y12 inhibitor with class I recommendation in patients after percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS). However, it is noted that patients with diabetes have reduced therapeutic response to clopidogrel. 

    Given this, a study was conducted to evaluate the antiplatelet effect of ticagrelor versus clopidogrel in patients with diabetes after recent PCI for CCS. The participants were randomly assigned to ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily, in addition to aspirin 100 mg once daily for 15 days.

    Results showed that the baseline characteristics of the patients (N=39) were well balanced between the two groups. Compared with the clopidogrel group (n=19), patients in the ticagrelor group (n=20) had lower P2Y12 reaction unit values, higher P2Y12 percentage inhibition, and fewer high on-treatment platelet reactivity, both before and 2–4 hours after the final study dose on day 15. No major or minor bleeding or serious adverse events occurred in either group.

    The findings indicated that ticagrelor achieved greater peak and trough platelet inhibition than clopidogrel in patients with diabetes who underwent PCI for CCS, suggesting its potential effectiveness in this patient group. 

    Reference: 
    Liu Z, et al. Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes. Thromb Haemost. 2020. doi: 10.1055/s-0040-1713375. [Epub ahead of print]